|
显示项目 654251-654300 / 2307984 (共46160页)
<< < 13081 13082 13083 13084 13085 13086 13087 13088 13089 13090 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2021-04-23T05:56:25Z |
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non�Vsmall Cell Lung Cancer
|
Yu H.A.;Paz-Ares L.G.;Chih-Hsin Yang;Lee K.H.;Garrido P.;Park K.;Kim J.-H.;Lee D.H.;Mao H.;Wijayawardana S.R.;Gao L.;Hozak R.R.;Chao B.H.;Planchard D.; Yu H.A.; Paz-Ares L.G.; CHIH-HSIN YANG; Lee K.H.; Garrido P.; Park K.; Kim J.-H.; Lee D.H.; Mao H.; Wijayawardana S.R.; Gao L.; Hozak R.R.; Chao B.H.; Planchard D. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Chia-Chi Lin;Takeuchi Y;Pronk L.C;Sarashina A;Cheng A.-L;Naito Y;Shitara K;Yang J.C.-H;Doi T; Doi T; Yang J.C.-H; Shitara K; Naito Y; Cheng A.-L; Sarashina A; Pronk L.C; Takeuchi Y; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T;Chih-Hsin Yang;Shitara K;Naito Y;Cheng A.-L;Sarashina A;Pronk L.C;Takeuchi Y;Lin C.-C.; Doi T; CHIH-HSIN YANG; Shitara K; Naito Y; Cheng A.-L; Sarashina A; Pronk L.C; Takeuchi Y; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T.; Yang J.C.-H.; Shitara K.; Naito Y.; ANN-LII CHENG; Sarashina A.; Pronk L.C.; Takeuchi Y.; Lin C.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:08Z |
Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor �] (TGF-�]) and PD-L1
|
Chia-Chi Lin; Doi T; Muro K; Hou M.-M; Esaki T; Hara H; Chung H.-C; Osada M; Helwig C; Kondo S. |
| 臺大學術典藏 |
2018-09-10T07:12:47Z |
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma
|
Yu, A.L. and Uttenreuther-Fischer, M.M. and Huang, C.S. and Tsui, C.C. and Gillies, S.D. and Reisfeld, R.A. and Kung, F.H.; CHIUN-SHENG HUANG |
| 臺大學術典藏 |
2020-03-23T07:19:40Z |
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma
|
Yu A.L.; Uttenreuther-Fischer M.M.; CHIUN-SHENG HUANG; Tsui C.C.; Gillies S.D.; Reisfeld R.A.; Kung F.H. |
| 國家衛生研究院 |
2016-02 |
Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC)
|
Chiang, NJ;Tsai, KK;Chen, JS;Yang, SH;Hsu, C;Shan, YS;Chen, LT |
| 國立成功大學 |
2016-02-01 |
Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC).
|
Chiang, Nai-Jung; Tsai, Kelvin K.; Chen, Jen-Shi; Yang, Shih-Hung; Hsu, Chiun; Shan, Yan-Shen; Chen, Li-Tzong |
| 國立成功大學 |
2000 |
Phase I trial of weekly short infusion of single agent docetaxel in patients with advanced NSCLC/MBC.
|
Pan, Hsing-Ju; Tasi, Meng-Yi; Huang, Guang-Chang; Huang, Wen-Tsung; Chen, Tsai-Yun; Su, Wu-Chou; Taso, Chao-Jung |
| 國立成功大學 |
2014-11 |
Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma
|
Lin, C.; Su, W.; Lee, J.; Hsu, C.; Cheng, A.; Lin, C.; Ho, H.; Huang, C.; Hsueh, S.; Yang, J |
| 國立成功大學 |
2016-12 |
Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma
|
Lin, C. C.; Su, W. C.; Chao, Y.; Lee, J. H.; Hsu, C. H.; Cheng, A. L.; Chung, W. P.; Chen, M. H.; Lin, C. L.; Ho, H. L.; Huang, L. P.; Huang, C. T.; Hsueh, S. P.; Yang, J. C. H. |
| 國立臺灣大學 |
2016 |
Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
|
Minami, Hironobu; Ando, Yuichi; Ma, Brigette Buig Yue; Lee, Jih-Hsiang; Momota, Hiroyuki; Fujiwara, Yutaka; Li, Leung; Fukino, Koichi; Ito, Koji; Tajima, Takeshi; Mori, Asuka; Lin, Chia-Chi; 林家齊; 李日翔 |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
|
Mori A; Tajima T; Ito K; Fukino K; Li L; Fujiwara Y; Momota H; Hsiang Lee J; Ma B.B.Y; Ando Y; Minami H; Chia-Chi Lin |
| 臺大學術典藏 |
2018-09-10T08:31:21Z |
Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers
|
Ho, Y.-F. Lu, W.-C. Chen, R.R.-L. Cheng, A.-L. Yeh, K.-H.; KUN-HUEI YEH; YUNN-FANG HO; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:09Z |
Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers
|
Ho Y.-F.; Lu W.-C.; Chen R.R.-L.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:42Z |
Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers
|
Ho Y.-F.;Lu W.-C.;Chen R.R.-L.;Cheng A.-L.;Kun-Huei Yeh; Ho Y.-F.; Lu W.-C.; Chen R.R.-L.; Cheng A.-L.; KUN-HUEI YEH |
| 國立臺灣大學 |
2009 |
Phase I, Pharmacokinetic, and Pharmacodynamic Study of Amg 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
|
林家齊; LIN, CHIA-CHI |
| 國家衛生研究院 |
2006-03 |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah, HS; Cheng, AL; Hsu, C; Hsu, CH; Liu, TW; Chang, JY; Jan, CM; Chao, Y; Yu, WL; Chuang, TR; Whang-Peng, J; Chen, LT |
| 臺大學術典藏 |
2022-08-19T00:21:12Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.; Cheng A.-L.; CHIUN HSU; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 國立臺灣大學 |
2006 |
Phase I-Ii Trial of Weekly Gemcitabine Plus High-Dose 5-Fluorouracil and Leucovorin in Advanced Pancreatic Cancer
|
鄭安理; 許駿; 徐志宏; 劉滄梧; 張俊彥; 詹昌明; 趙毅; 尤維蘭; 彭汪嘉康; 陳立宗; CHENG, ANN-LII; HSU, CHIUN; HSU, CHIH-HUNG; LIU, TSANG-WU; CHANG, JANG-YANG; JAN, CHANG-MING; CHAO, YEE; YU, WEI-LAN; WHANG-PENG, JACQUELINE; CHEN, LI-TZONG |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Chen L.-T.; Shiah H.-S.;Cheng A.-L.;Chiun Hsu;Hsu C.-H.;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Chiun Hsu; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.;Cheng A.-L.;Hsu C.;Chih-Hung Hsu;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Hsu C.; CHIH-HUNG HSU; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T02:02:13Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.; ANN-LII CHENG; Hsu C.; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 高雄醫學大學 |
2006 |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
|
鄭安理;林肇堂;詹昌明;彭汪嘉康;陳立宗 ; Shiah HS;Cheng AL;Hsu C;Hsu CH;Liu TW;Chang JY;Jan CM;Chao Y;Yu WL;Chuang TR;Whang-Peng J;Chen LT |
| 臺大學術典藏 |
2021-07-21T23:21:29Z |
Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors
|
Curigliano, Giuseppe; Gelderblom, Hans; Mach, Nicolas; Doi, Toshihiko; Tai, David; Forde, Patrick M.; Sarantopoulos, John; Bedard, Philippe L.; Chia-Chi Lin; Stephen Hodi, F.; Wilgenhof, Sofie; Santoro, Armando; Sabatos-Peyton, Catherine A.; Longmire, Tyler A.; Xyrafas, Alexandros; Sun, Haiying; Gutzwiller, Sabine; Manenti, Luigi; Naing, Aung |
| 臺大學術典藏 |
2022-09-15T01:08:48Z |
Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors
|
Curigliano G.; Gelderblom H.; Mach N.; Doi T.; Tai D.; Forde P.M.; Sarantopoulos J.; Bedard P.L.; Chia-Chi Lin; Stephen Hodi F.; Wilgenhof S.; Santoro A.; Sabatos-Peyton C.A.; Longmire T.A.; Xyrafas A.; Sun H.; Gutzwiller S.; Manenti L.; Naing A. |
| 國立臺灣大學 |
2008 |
Phase I/II study of a new autologous transplantation method for vitiligo treatment.
|
Chen, WYJ; Hong, JB; She, BR; Chan, CC; Chiu, HC; Lin, SJ |
| 國家衛生研究院 |
2008-05 |
Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma
|
Yen, Y;So, S;Rose, M;Saif, MW;Chu, E;Chen, L;Liu, S;Foo, A;Tilton, R;Cheng, Y |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer
|
Chia-Chi Lin; Taylor M; Boni V; Brunsvig P.F; Geater S.L; Salvagni S; Garrido Lopez P; ?zg?ro?lu M; Sriuranpong V; Ponce Aix S; Ascierto P.A; Fasolo A; Sezer A; Kowalski D.M; Faris J.E; Cameron S; Mataraza J; Wu H; Antona V; Ochoa de Olza M. |
| 國立臺灣大學 |
2008 |
Phase I/Ii Trail of Cultured Autologous Melanocytes and a New Transplantation Method for Vitiligo Treatment
|
洪楨邦; 詹融怡; 邱顯清; 林頌然; HONG, JIN-BON; CHAN, JUNG-YI; CHIU, HSIEN-CHING; LIN, SUNG-JAN |
| 國立臺灣大學 |
2008 |
Phase I/II trail of cultured autologous melanocytes and a new transplantation method for vitiligo treatment.
|
Hong, JB; She, BR; Chan, CC; Chiu, HC; Lin, SJ |
| 臺大學術典藏 |
2022-09-15T01:08:56Z |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai J.; Deva S.; Lee J.S.; Chia-Chi Lin; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. |
| 國立成功大學 |
2020 |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai, J.;Deva, S.;Lee, J.S.;Lin, C.-C.;Yen, C.-J.;Chao, Y.;Keam, B.;Jameson, M.;Hou, M.-M.;Kang, Y.-K.;Markman, B.;Lu, C.-H.;Rau, K.-M.;Lee, K.-H.;Horvath, L.;Friedlander, M.;Hill, A.;Sandhu, Sandhu S.;Barlow, P.;Wu, C.-Y.;Zhang, Y.;Liang, Liang L.;Wu, J.;Paton, V.;Millward, Millward M. |
| 國立成功大學 |
2012-05 |
Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)
|
Cheng, AL (Cheng, Ann-Lii); Kang, YK (Kang, Yoon-Koo); Ryoo, BY (Ryoo, Baek-Yeol); Yen, CJ (Yen, Chia-Jui); Lim, HY (Lim, Ho Yeong); Oh, DY (Oh, Do-Youn); Austin, T (Austin, TaShara); Wang, Q (Wang, Qiang); Greenberg, J (Greenberg, Jonathan); Beckman, RA (Beckman, Robert A.); Kudo, M (Kudo, Masatoshi) |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Morikawa H.; Maki Y.; Tanaka T.; Ohtomo T.; Schwartz L.; Smith-Jones P.M.; Frenette C.; O’Neil B.; Shao Y.-Y.; Wan P.; Ma J.; Gansukh B.; Lyashchenko S.K.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Yen C.-J.; CHIH-HUNG HSU; Abou-Alfa G.K.; Abou-Alfa G.K.;Yen C.-J.;Chih-Hung Hsu;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Shao Y.-Y.;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Lin Z.-Z. |
| 臺大學術典藏 |
2021-08-11T03:46:39Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG; Carrasquilo J.A. |
| 臺大學術典藏 |
2022-06-10T06:11:00Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 國立成功大學 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa, G.K.;Yen, C.-J.;Hsu, C.-H.;O’Donoghue, J.;Beylergil, V.;Ruan, S.;Pandit-Taskar, N.;Gansukh, B.;Lyashchenko, S.K.;Ma, J.;Wan, P.;Shao, Y.-Y.;Lin, Z.-Z.;Frenette, C.;O’Neil, B.;Schwartz, L.;Smith-Jones, P.M.;Ohtomo, T.;Tanaka, Tanaka T.;Morikawa, H.;Maki, Y.;Ohishi, N.;Chen, Y.-C.;Agajanov, T.;Boisserie, F.;Di, Laurenzio L.;Lee, R.;Larson, S.M.;Cheng, A.-L.;Carrasquilo, J.A. |
| 臺大學術典藏 |
2021-03-03T10:26:43Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HRþ advanced breast cancer
|
Tolaney, Sara M.; Im, Young Hyuck; Calvo, Emiliano; Yen-Shen Lu; Hamilton, Erika; Forero-Torres, Andres; Bachelot, Thomas; Maur, Michela; Fasolo, Angelica; Tiedt, Ralph; Nardi, Lisa; Stammberger, Uz; Abdelhady, Ahmed M.; Ruan, Shiling; Lee, Soo Chin |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer
|
Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. |
| 國立成功大學 |
2023 |
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
|
Camidge, D.R.;Barlesi, F.;Goldman, J.W.;Morgensztern, D.;Heist, R.;Vokes, E.;Spira, A.;Angevin, E.;Su, W.-C.;Hong, D.S.;Strickler, J.H.;Motwani, Motwani M.;Dunbar, M.;Parikh, A.;Noon, E.;Blot, V.;Wu, J.;Kelly, Kelly K. |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 國立成功大學 |
2018 |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Wu, Y.-L.;Zhang, L.;Kim, D.-W.;Liu, X.;Lee, D.H.;Yang, J.C.-H.;Ahn, M.-J.;Vansteenkiste, J.F.;Su, W.-C.;Felip, E.;Chia, V.;Glaser, S.;Pultar, Pultar P.;Zhao, S.;Peng, B.;Akimov, M.;Tan, D.S.W. |
| 國立成功大學 |
2022 |
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer
|
Santoro, A.;Su, W.-C.;Navarro, A.;Simonelli, M.;CH, Yang J.;Ardizzoni, Ardizzoni A.;Barlesi, F.;Hyoung, Kang J.;DiDominick, S.;Abdelhady, Abdelhady A.;Chen, X.;Stammberger, U.;Felip, E. |
| 國立交通大學 |
2014-12-08T15:04:52Z |
PHASE IDENTIFICATION AND ELECTRICAL-PROPERTIES IN ZNO-GLASS VARISTORS
|
LEE, YS; TSENG, TY |
| 臺大學術典藏 |
2002 |
Phase Identification And Growth Kinetics of the Intermetallic Compounds Formed during In-49Sn/Cu Soldering Reactions
|
ChuangTH; Wang, S. S.; Chang, S. Y.; Yu, C. L.; Chuang, T. H.; Yu, C. L.; Chang, S. Y.; Wang, S. S.; Chuang, T. H. |
| 國立臺灣大學 |
2002 |
Phase Identification And Growth Kinetics of the Intermetallic Compounds Formed during In-49Sn/Cu Soldering Reactions
|
Chuang, T. H.; Yu, C. L.; Chang, S. Y.; Wang, S. S. |
显示项目 654251-654300 / 2307984 (共46160页)
<< < 13081 13082 13083 13084 13085 13086 13087 13088 13089 13090 > >>
每页显示[10|25|50]项目
|
